Telomere Inhibition and Telomere Disruption as Processes for Drug Targeting

Annual Review of Pharmacology and Toxicology

Volumn 43, Issue , 2003, Pages 359-379

  Rezler, Evonne M ^a   Bearss, David J ^c   Hurley, Laurence H ^a,b,c  

^a UNIVERSITY OF ARIZONA   (United States)

^b University of Arizona   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

Author keywords

Antisense; G quadruplex; hTERT; hTR; Ribozymes

Indexed keywords

9 ANILINOPROFLAVINE; ACRIDINE DERIVATIVE; ANTISENSE OLIGONUCLEOTIDE; BSU 1051; FLUOROQUINOPHENOXAZINE; MYC PROTEIN; PROTEIN P53; RIBOZYME; TAQ POLYMERASE; TELOMERASE; TELOMERASE INHIBITOR; TELOMESTATIN; TRIAZINE; UNCLASSIFIED DRUG; WP 631; ENZYME INHIBITOR;

CANCER CELL; CELL IMMORTALIZATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DRUG TARGETING; ENZYME INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROTEIN STRUCTURE; REVIEW; TELOMERE; TELOMERIC REPEAT AMPLIFICATION PROTOCOL; ANIMAL; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFECT; METABOLISM; METHODOLOGY;

ANIMALS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; OLIGONUCLEOTIDES, ANTISENSE; TELOMERASE; TELOMERE;

EID: 0037889841     PISSN: 03621642     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.pharmtox.43.100901.135733     Document Type: Review

References (103)

1. Nakamura TM, Morin GB, Chapman KB, Weinrich SL, Andrews WH, et al. 1997. Telomerase catalytic subunit homologs from fission yeast and human. Science 277:955-59
2. Meyerson M, Counter CM, Eaton EN, Ellisen LW, Steiner P, et al. 1997. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 90:785-95
3. Kilian A, Bowtell DD, Abud HE, Hime GR, Venter DJ, et al. 1997. Isolation of a candidate human telomerase catalytic subunit gene, which reveals complex splicing patterns in different cell types. Hum. Mol. Genet. 6:2011-19
4. Feng J, Funk WD, Wang SS, Weinrich SL, Avilion AA, et al. 1995. The RNA component of human telomerase. Science 269:1236-41
5. Harrington L, Zhou W, McPhail T, Oulton R, Yeung DS, et al. 1997. Human telomerase contains evolutionarily conserved catalytic and structural subunits. Genes Dev. 11:3109-15
6. Akalin A, Elmore LW, Forsythe HL, Amaker BA, McCollum ED, et al. 2001. A novel mechanism for chaperone-mediated telomerase regulation during prostate cancer progression. Cancer Res. 61:4791-96
7. Forsythe HL, Jarvis JL, Turner JW, Elmore LW, Holt SE. 2001. Stable association of Hsp90 and p23, but not Hsp70, with active human telomerase. J. Biol. Chem. 276:15571-74
8. Yu CC, Lo SC, Wang TC. 2001. Telomerase is regulated by protein kinase C-ζ in human nasopharyngeal cancer cells. Biochem. J. 355:459-64
9. Kang SS, Kwon T, Kwon DY, Do SI. 1999. Akt protein kinase enhances human telomerase activity through phosphorylation of telomerase reverse transcriptase subunit. J. Biol. Chem. 274:13085-90
10. Li H, Zhao L, Yang Z, Funder JW, Liu JP. 1998. Telomerase is controlled by protein kinase Cα in human breast cancer cells. J. Biol. Chem. 273:33436-42
11. Kharbanda S, Kumar V, Dhar S, Pandey P, Chen C, et al. 2000. Regulation of the hTERT telomerase catalytic subunit by the c-Abl tyrosine kinase. Curr. Biol. 10:568-75
12. Sun D, Lopez-Guajardo CC, Quada J, Hurley LH, Von Hoff DD. 1999. Regulation of catalytic activity and processivity of human telomerase. Biochemistry 38:4037-44
13. Peng Y, Mian IS, Lue NF. 2001. Analysis of telomerase processivity: mechanistic similarity to HIV-1 reverse transcriptase and role in telomere maintenance. Mol. Cell 7:1201-11
14. Blackburn EH, Gall JG. 1978. A tandemly repeated sequence at the termini of extrachromosomal ribosomal RNA genes in Tetrahymena. J. Mol. Biol. 120:33-53
15. Allshire RC, Dempster M, Hastie ND. 1989. Human telomeres contain at least three types of G-rich repeats distributed non-randomly. Nucleic Acids Res. 17: 4611-27
16. de Lange T, Shine L, Myers RM, Cox DR, Naylor SL, et al. 1990. Structure and variability of human chromosome ends. Mol. Cell Biol. 10:518-27
17. n, present at the telomeres of human chromosomes. Proc. Natl. Acad. Sci. USA 85:6622-26
18. Griffith JD, Comeau L, Rosenfield S, Stansel RM, Bianchi A, et al. 1999. Mammalian telomeres end in a large duplex loop. Cell 97:503-14
19. Makarov VL, Hirose Y, Langmore JP. 1997. Long G tails at both ends of human chromosomes suggest a C strand degradation mechanism for telomere shortening. Cell 88:657-66
20. Wright WE, Tesmer VM, Huffman KE, Levene SD, Shay JW. 1997. Normal human chromosomes have long G-rich telomeric overhangs at one end. Genes Dev. 11:2801-9
21. Colgin LM, Reddel RR. 1999. Telomere maintenance mechanisms and cellular immortalization. Curr. Opin. Genet. Dev. 9:97-103
22. Harley CB, Futcher AB, Greider CW. 1990. Telomeres shorten during ageing of human fibroblasts. Nature 345:458-60
23. Counter CM, Avilion AA, LeFeuvre CE, Stewart NG, Greider CW, et al. 1992. Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J. 11:1921-29
24. Harley CB. 1995. Telomeres and aging. In Telomeres, ed. EH Blackburn, CW Greider, pp. 247-63. Plainview, NY: Cold Spring Harbor Lab.
25. van Steensel B, Smogorzewska A, de Lange T. 1998. TRF2 protects human telomeres from end-to-end fusions. Cell 92:401-13
26. de Lange T, Jacks T. 1999. For better or worse? Telomerase inhibition and cancer. Cell 98:273-75
27. Hastie ND, Dempster M, Dunlap MG, Thompsson AM, Green DK, Allshire RC. 1990. Telomere reduction in human colorectal carcinoma with aging. Nature 346:866-68
28. Mehle C, Ljungberg B, Roos G. 1994. Telomere shortening in renal cell carcinoma. Cancer Res. 54:236-41
29. Watson JD. 1972. Origin of concatemeric T7 DNA. Nat. New Biol. 239:197-201
30. Olovnikov AM. 1973. A theory of marginotomy. The incomplete copying of template margin in enzymic synthesis of polynucleotides and biological significance of the phenomenon. J. Theor. Biol. 41:181-90
31. Wellinger RJ, Ethier K, Labrecque P, Zakian VA. 1996. Evidence for a new step in telomere maintenance. Cell 85:423-33
32. Friberg S, Mattson S. 1997. On the growth rates of human malignant tumors: implications for medical decision making. J. Surg. Oncol. 65:284-97
33. Karlseder J, Smogorzewska A, de Lange T 2002. Senescence induced by altered telomere state, not telomere loss. Science 295:2446-49
34. Blackburn EH. 2000. Telomere states and cell fates. Nature 408:53-56
35. Blackburn EH. 2001. Switching and signaling at the telomere. Cell 106:661-73
36. Broccoli D, Smogorzewska A, Chong L, de Lange T. 1997. Human telomeres contain two distinct Myb-related proteins, TRF1 and TRF2. Nat. Genet. 17:231-35
37. Karlseder J, Broccoli D, Dai Y, Hardy S, de Lange T. 1999. p53 and ATM dependent apoptosis induced by telomeres lacking TRF2. Science 283:1321-25
38. Galy V, Olivo-Marin JC, Scherthan H, Doye V, Rascalou N, Nehrbass U. 2000. Nuclear pore complexes in the organization of silent telomeric chromatin. Nature 403:108-12
39. Baumann P, Cech TR. 2000. Protection of telomeres by the Ku protein in fission yeast. Mol. Biol. Cell 11:3265-75
40. Gasser SM. 2000. A sense of the end. Science 288:1377-79
41. Holt SE, Aisner DL, Baur J, Tesmer VM, Dy M, et al. 1999. Functional requirements of p23 and Hsp90 in telomerase complexes. Genes Dev. 13:817-26
42. Webb A, Cunningham D, Cotter F, Clarke PA, di Stefano F, et al. 1997. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet 349:1137-41
43. Ludwig A, Saretzki G, Holm PS, Tiemann F, Lorenz M, et al. 2001. Ribozyme cleavage of telomerase mRNA sensitizes breast epithelial cells to inhibitors of topoisomerase. Cancer Res. 61:3053-61
44. Li H, Zhao LL, Funder JW, Liu JP. 1997. Protein phosphatase 2A inhibits nuclear telomerase activity in human breast cancer cells. J. Biol. Chem. 272:16729-32
45. Ku WC, Cheng AJ, Wang TC. 1997. Inhibition of telomerase activity by PKC inhibitors in human nasopharyngeal cancer cells in culture. Biochem. Biophys. Res. Commun. 241:730-:36
46. Bodnar AG, Kim NW, Effros RB, Chiu CP. 1996. Mechanism of telomerase induction during T cell activation. Exp. Cell Res. 228:58-64
47. Kyo S, Takakura M, Taira T, Kanaya T, Itoh H, et al. 2000. Sp1 cooperates with c-Myc to activate transcription of the human telomerase reverse transcriptase gene (hTERT). Nucleic Acids Res. 28:669-77
48. Wang J, Xie LY, Allan S, Beach D, Hannon GJ. 1998. Myc activates telomerase. Genes Dev. 12:1769-74
49. Greenberg RA, O'Hagan RC, Deng H, Xiao Q, Hann SR, et al. 1999. Telomerase reverse transcriptase gene is a direct target of c-Myc but is not functionally equivalent in cellular transformation. Oncogene 18:1219-26
50. Grand CL, Han H, Muñoz RM, Weitman S, Von Hoff DD, et al. 2002. The cationic porphyrin TMPyP4 downregulates c-MYC and hTERT expression and inhibits tumor growth in vivo. Mol. Cancer Ther. 1:565-73
51. Siddiqui-Jain A, Grand CL, Bearss DJ, Hurley LH. 2002. Direct evidence for a G-quadruplex in a promoter region and its targeting with a small molecule to repress c-MYC transcription. Proc. Natl. Acad. Sci. USA 99:11593-98
52. Villamarin S, Ferrer-Miralles N, Mansilla S, Priebe W, Portugal J. 2002. Induction of G(2)/M arrest and inhibition of c-myc and p53 transcription by WP631 in Jurkat T lymphocytes. Biochem. Pharmacol. 63:1251-58
53. Norton JC, Piatyszek MA, Wright WE, Shay JW, Corey DR. 1996. Inhibition of human telomerase activity by peptide nucleic acids. Nat. Biotechnol. 14:615-19
54. Hamilton SE, Simmons CG, Kathiriya IS, Corey DR. 1999. Cellular delivery of peptide nucleic acids and inhibition of human telomerase. Chem. Biol. 6:343-51
55. Braasch DA, Corey DR. 2001. Locked nucleic acid (LNA): fine-tuning the recognition of DNA and RNA. Chem. Biol. 8:1-7
56. Gryaznov S, Pongracz K, Matray T, Schultz R, Pruzan R, et al. 2001. Telomerase inhibitors - oligonucleotide phosphoramidates as potential therapeutic agents. Nucleosides Nucleotides Nucleic Acids 20:401-10
57. Pitts AE, Corey DR. 1998. Inhibition of human telomerase by 2′-O-methyl-RNA. Proc. Natl. Acad. Sci. USA 95:11549-54
58. Herbert B, Pitts AE, Baker SI, Hamilton SE, Wright WE, et al. 1999. Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death. Proc. Natl. Acad. Sci. USA 96:14276-81
59. Elayadi AN, Demieville A, Wancewicz EV, Monia BP, Corey DR. 2001. Inhibition of telomerase by 2′-O-(2-methoxyethyl) RNA oligomers: effect of length, phosphorothioate substitution and time inside cells. Nucleic Acids Res. 29:1683-89
60. Corey DR. 2002. Telomerase inhibition, oligonucleotides, and clinical trials. Oncogene 21:631-37
61. Perry PJ, Arnold JR, Jenkins TC. 2001. Telomerase inhibitors for the treatment of cancer: the current perspective. Expert Opin. Investig. Drugs 10:2141-56
62. Mergny JL, Riou JF, Mailliet P, Teulade-Fichou MP, Gilson E. 2002. Natural and pharmacological regulation of telomerase. Nucleic Acids Res. 30:839-65
63. Kushner DM, Paranjape JM, Bandyopadhyay B, Cramer H, Leaman DW, et al. 2000. 2-5A antisense directed against telomerase RNA produces apoptosis in ovarian cancer cells. Gynecol. Oncol. 76:183-92
64. Kondo Y, Koga S, Komata T, Kondo S. 2000. Treatment of prostate cancer in vitro and in vivo with 2-5A-anti-telomerase RNA component. Oncogene 19:2205-11
65. Koga S, Kondo Y, Komata T, Kondo S. 2001. Treatment of bladder cancer cells in vitro and in vivo with 2-5A antisense telomerase RNA. Gene Ther. 8:654-58
66. Kondo Y, Komata T, Kondo S. 2001. Combination therapy of 2-5A antisense against telomerase RNA and cisplatin for malignant gliomas. Int. J. Oncol. 18:1287-92
67. Kanazawa Y, Ohkawa K, Ueda K, Mita E, Takehara T, et al. 1996. Hammerhead ribozyme-mediated inhibition of telomerase activity in extracts of human hepatocellular carcinoma cells. Biochem. Biophys. Res. Commun. 225:570-76
68. Yokoyama Y. 2001. Hammerhead ribozymes to modulate telomerase activity of endometrial carcinoma cells. Human Cell 14:223-31
69. Yokoyama Y, Takahashi Y, Shinohara A, Lian Z, Wan X, et al. 1998. Attenuation of telomerase activity by a hammerhead ribozyme targeting the template region of telomerase RNA in endometrial carcinoma cells. Cancer Res. 58:5406-10
70. Folini M, Colella G, Villa R, Lualdi S, Daidone MG, Zaffaroni N. 2000. Inhibition of telomerase activity by a hammerhead ribozyme targeting the RNA component of telomerase in human melanoma cells. J. Invest. Dermatol. 11:259-67
71. Pascolo E, Wenz C, Lingner J, Hauel N, Priepke H, et al. 2002. Mechanism of human telomerase inhibition by BIBR1532, a synthetic, non-nucleosidic drug candidate. J. Biol. Chem. 277:15566-72
72. Damm K, Hemmann U, Garin-Chesa P, Hauel N, Kauffmann I, et al. 2001. A highly selective telomerase inhibitor limiting human cancer cell proliferation. EMBO J. 20:6958-68
73. Fletcher TM, Cathers BE, Ravikumar KS, Mamiya BM, Kerwin SM. 2001. Inhibition of human telomerase by 7-deaza-2′-deoxyguanosine nucleoside triphosphate analogs: potent inhibition by 6-thio-7-deaza-2′ -deoxyguanosine 5′-triphosphate. Bioorg. Chem. 29:36-55
74. Tendian SW, Parker WB. 2000. Interaction of deoxyguanosine nucleotide analogs with human telomerase. Mol. Pharmacol. 57:695-99
75. Zahler AM, Williamson JR, Cech TR, Prescott DM. 1991. Inhibition of telomerase by G-quartet DNA structures. Nature 350:718-20
76. 3] G-tetraplex. Structure 1: 263-82
77. Sun D, Thompson B, Cathers BE, Salazar M, Kerwin SM, et al. 1997. Inhibition of human telomerase by a G-quadruplex-interactive compound. J. Med. Chem. 40: 2113-16
78. Sun D, Hurley LH, Von Hoff DD. 1998. Telomerase assay using biotinylated-primer extension and magnetic separation of the products. BioTechniques 25:1046-51
79. Duan W, Rangan A, Vankayalapati H, Kim MY, Zeng Q, et al. 2001. Design and synthesis of fluoroquinophenoxazines that interact with human telomeric G-quadruplexes and their biological effects. Mol. Cancer Ther. 1:103-20
80. Izbicka E, Wheelhouse RT, Raymond E, Davidson K, Lawrence L, et al. 1999. Effects of cationic porphyrins as G-quadruplex interactive agents (QIAs) in human tumor cells. Cancer Res. 59:639-44
81. Riou JF, Guittat L, Mailliet P, Laoui A, Renou E, et al. 2002. Cell senescence and telomere shortening induced by a new series of specific G-quadruplex DNA ligands. Proc. Natl. Acad. Sci. USA 99:2672-77
82. Dunham MA, Neumann AA, Fasching CL, Reddel RR. 2000. Telomere maintenance by recombination in human cells. Nat. Genet. 26:447-50
83. Ellis NA, Groden J, Ye TZ, Straughen J, Lennon DJ, et al. 1995. The Bloom's syndrome gene product is homologous to RecQ helicases. Cell 83:655-66
84. Karow JK, Chakraverty RK, Hickson ID. 1997. The Bloom's syndrome gene product is a 3′-5′ DNA helicase. J. Biol. Chem. 272:30611-14
85. Lin Y-C, Shih J-W, Hsu C-L, Lin J-J. 2002. Binding and partial denaturing of G-quartet DNA by Cdc13p of Saccharomyces cerevisiae. J. Biol. Chem. 276:47671-74
86. Suzuki N, Shimamoto A, Imamura O, Kuromitsu J, Kitao S, et al. 1997. DNA helicase activity in Werner's syndrome gene product synthesized in a baculovirus system. Nucleic Acids Res. 25:2973-78
87. Yu CE, Oshima J, Fu YH, Wijsman EM, Hisama F, et al. 1996. Positional cloning of the Werner's syndrome gene. Science 272:258-62
88. Han H, Bennett RJ, Hurley LH. 2000. Inhibition of unwinding of G-quadruplex structures by Sgs1 helicase in the presence of N,N′ -bis[2-(1-piperidino)ethyl]-3,4,9,10-perylenetetracarboxylic diimide, a G-quadruplex-interactive ligand. Biochemistry 39:5295-302
89. Han H, Cliff CL, Hurley LH. 1999. Accelerated assembly of G-quadruplex structures by a small molecule. Biochemistry 38:6981-86
90. Li J-L, Harrison JH, Reszka AP, Brosh RM Jr, Bohr VA, et al. 2001. Inhibition of the Bloom's and Werner's syndrome helicases by G-quadruplex interacting ligands. Biochemistry 40:15194-202
91. Kim MY, Vankayalapati H, Shin-Ya K, Wierzba K, Hurley LH. 2002. Telomestatin, a potent telomerase inhibitor that interacts quite specifically with the human telomeric intramolecular G-quadruplex. J. Am. Chem. Soc. 124:2098-99
92. Han H, Langley DR, Rangan A, Hurley LH. 2001. Selective interactions of cationic porphyrins with G-quadruplex structures. J. Am. Chem. Soc. 123:8902-13
93. Mergny JL, Mailliet P, Lavelle F, Riou JF, Laoui A, Hélène C. 1999. The development of telomerase inhibitors: the G-quartet approach. Anti-Cancer Drug Des. 14:327-39
94. Read M, Harrison RJ, Romagnoli B, Tanious FA, Gowan SH, et al. 2001. Structure-based design of selective and potent G-quadruplex-mediated telomerase inhibitors. Proc. Natl. Acad. Sci. USA 98: 4844-49
95. Koeppel F, Riou JF, Laoui A, Mailliet P, Arimondo PB, et al. 2001. Ethidium derivatives bind to G-quartets, inhibit telomerase and act as fluorescent probes for quadruplexes. Nucleic Acids Res. 29:1087-96
96. Gowan SM, Heald R, Stevens MF, Kelland LR. 2001. Potent inhibition of telomerase by small-molecule pentacyclic acridines capable of interacting with G-quadruplexes. Mol. Pharmacol. 60:981-88
97. Izbicka E, Nishioka D, Marcell V, Raymond E, Davidson KK, et al. 1999. Telomere-interactive agents affect proliferation rates and induce chromosomal destabilization in sea urchin embryos. Anti-Cancer Drug Des. 14:355-65
98. Shin-Ya K, Wierzba K, Matsuo K, Ohtani T, Yamada Y, et al. 2001. Telomestatin, a novel telomerase inhibitor from Streptomyces anulatus. J. Am. Chem. Soc. 123:1262-63
99. Mergny JL, Hélène C. 1998. G-quadruplex DNA: a target for drug design. Nat. Med. 4:1366-67
100. Han H, Hurley LH. 2000. G-quadruplex DNA: a potential target for anti-cancer drug design. Trends Pharmacol. Sci. 21: 136-42
101. Kerwin SM. 2000. G-Quadruplex DNA as a target for drug design. Curr. Pharm. Des. 6:441-78
102. Hurley LH. 2002. DNA and its associated processes as targets for cancer therapy. Nat. Rev. Cancer 2:188-200
103. Ren J, Chaires JB. 1999. Sequence and structural selectivity of nucleic acid binding ligands. Biochemistry 38:16067-75